Here are 1-3 brief analogies to describe XORTX Therapeutics:

• They're like a startup Pfizer or Merck focused specifically on developing new therapies for kidney and metabolic diseases.
• Imagine an early-stage Eli Lilly or Novo Nordisk, but with a strong emphasis on kidney diseases and related metabolic disorders.

• XRx-008: A late clinical stage program therapy for autosomal dominant polycystic kidney disease.
• XRx-101: An uric acid lowering agent used to treat patients with COVID-19 infection, and for the suppression of acute kidney injury.
• XRx-221: A xanthine oxidase inhibitor candidate for the treatment of diabetic nephropathy.

Major Customers of XORTX Therapeutics (XRTX)

Based on the provided company description, XORTX Therapeutics Inc. is a biopharmaceutical company focused on the development and clinical-stage testing of therapies. Its drug candidates, such as XRx-008, XRx-101, and XRx-221, are currently in various stages of development, including late clinical stages. The description does not indicate that any of the company's therapies have been commercialized or are currently generating sales revenue from customers.

Therefore, XORTX Therapeutics currently does not have major commercial customers for its therapies. As a company primarily engaged in research and development, its activities are centered on bringing these therapies through clinical trials and regulatory approval.

If and when XORTX Therapeutics successfully commercializes its drug candidates, its typical customers would likely include:

• Pharmaceutical wholesalers and distributors
• Hospitals, clinics, and other healthcare institutions
• Pharmacies

The end-users of these therapies would be individuals (patients) suffering from the conditions the company aims to treat, but the direct sales would typically be to the entities listed above.

Dr. Allen W. Davidoff, PhD, Chief Executive Officer

Dr. Allen Davidoff is the founder and CEO of XORTX Therapeutics, with 15 years of drug development experience. Prior to forming XORTX, he was the Chief Scientific Officer, VP Product Development, and co-founder of Stem Cell Therapeutics Corp., and Senior Scientist and Head of Pharmacology at Cardiome Pharma Corp. He has broad clinical and regulatory experience, including involvement in two investigational new drug (IND) applications, two Phase I studies, seven Phase II studies, and one New Drug Application (NDA).

Dr. Michael Bumby, DVM, MBA, Chief Financial Officer

Dr. Michael Bumby joined XORTX Therapeutics as Chief Financial Officer on December 19, 2024. He brings over 20 years of finance and leadership experience in the biotech and pharma industries. Dr. Bumby previously served as CFO for six years at VIVO Cannabis Inc., which was successfully acquired by MediPharm Labs. He had a 14-year career at Eli Lilly, with roles in corporate finance and investment banking. As a public company CFO, he helped Antibe Therapeutics go public via an Initial Public Offering in 2013, and co-led the acquisition of Merus Labs by Norgine B.V. for $340 million in 2017.

Dr. Stephen Haworth, Chief Medical Officer

Dr. Stephen Haworth has over 25 years of successful global drug development and senior leadership experience in both startup and Fortune 500 pharmaceutical firms across the US and Europe. His extensive clinical and regulatory experience spans infectious disease, nephrology, cardiovascular disease, and programs for the treatment and prevention of SARS-CoV infection. He has held key roles in numerous FDA and EMA submissions and has been involved in several licensing and M&A transactions.

Dr. David MacDonald, Chief Technology Officer

Dr. David MacDonald has a record of over 30 years of achievement in drug development and leadership within the pharmaceutical and biotech sectors. Before joining XORTX, he held positions as CTO and later President of MSI Methylation Sciences Inc., a clinical-stage pharmaceutical company. Additionally, he previously served as President and CEO of Active Pass Pharmaceutics.

Anthony J. Giovinazzo, MBA, C. Dir., A.C.C., Chairman of the Board

Anthony J. Giovinazzo is an internationally recognized expert in intellectual property, drug development, and commercialization, with over 25 years of experience. He was the co-inventor, Chief Executive Officer, and Director of Cynapsus Therapeutics, a NASDAQ-listed specialty pharmaceutical company. At Cynapsus, he built the leadership team, set strategy, and raised US $136 million, including an over-subscribed IPO and NASDAQ listing. He also led negotiations for the CAD $841 million all-cash acquisition of Cynapsus by Sunovion Pharmaceuticals (Dainippon Sumitomo Pharmaceuticals).

Key risks to XORTX Therapeutics (XRTX) include:

• Clinical Trial Success and Regulatory Approval Risk: As a biopharmaceutical company, XORTX Therapeutics' future success is heavily dependent on the successful outcome of its clinical trials, particularly for its late clinical stage program, XRx-008, for autosomal dominant polycystic kidney disease. Any delays, failures in clinical trials, or inability to obtain regulatory approvals from agencies such as the FDA would significantly jeopardize the company's ability to commercialize its product candidates and could materially harm its business and financial prospects.
• Funding and Liquidity Risk: Developing new pharmaceutical therapies is a capital-intensive process. XORTX Therapeutics requires substantial ongoing funding to support its research and development activities, clinical trials, and operational expenses. The company's ability to raise additional capital on acceptable terms, or at all, is critical for advancing its pipeline. A failure to secure adequate funding could lead to delays, scaling back, or discontinuation of its development programs.
• Reliance on a Limited Pipeline: While XORTX Therapeutics has multiple programs, XRx-008 is highlighted as being in a "late clinical stage." A significant portion of the company's value and future prospects may be tied to the success of a limited number of drug candidates. A setback for a key program, such as XRx-008, could have a disproportionately negative impact on the company's overall business, even if other early-stage candidates are progressing.

The addressable markets for XORTX Therapeutics Inc.'s main products are as follows:

• XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The global Autosomal Dominant Polycystic Kidney Disease market is estimated to be valued at approximately USD 1.66 billion in 2025 and is expected to reach USD 2.56 billion by 2032, growing at a compound annual growth rate (CAGR) of 6.4% from 2025 to 2032. Another report projects the global ADPKD market to be valued at USD 2.7 billion in 2024 and grow to USD 3.8 billion by 2030 at a 5.9% CAGR. The market in the 7 major markets (US, EU4, UK, and Japan) was approximately USD 1,476.9 million in 2023, with the US accounting for approximately USD 889.8 million. The demand for ADPKD treatment in the USA is projected to grow from USD 0.6 billion in 2025 to USD 1.0 billion by 2035.
• XRx-101 for COVID-19 infection (uric acid lowering agent, acute kidney injury and associated health consequences):

  For Acute Kidney Injury (AKI), the global acute kidney injury treatment market is estimated to be valued at USD 1.96 billion in 2025 and is expected to reach USD 3.43 billion by 2032, exhibiting a CAGR of 8.3% from 2025 to 2032. North America is anticipated to hold the largest share of this market, with an estimated market share of 40.8% in 2025. Another source indicates the global acute kidney injury treatment market was valued at USD 6.10 billion in 2024 and is projected to reach USD 9.49 billion by 2033. The acute kidney injury market across the top 7 markets (US, EU4, UK, and Japan) reached a value of USD 6,057.1 million in 2024 and is expected to reach USD 10,185.6 million by 2035.

  For Hyperuricemia, the global hyperuricemia market reached USD 1.6 billion in 2022 and is expected to reach USD 3.4 billion by 2030, growing with a CAGR of 5.4% during the forecast period 2023-2030. The global hyperuricemia drugs market is projected to reach a value of USD 3.2 billion by 2033, exhibiting a CAGR of 4.2% during the forecast period (2025-2033). North America emerged as the largest regional market for hyperuricemia drugs in 2025. The 7 major hyperuricemia markets are expected to exhibit a CAGR of 9.01% during 2025-2035.

• XRx-221 for Diabetic Nephropathy: The global diabetic nephropathy market is estimated to reach a size of USD 3.7 billion in 2025 and is predicted to rise at a CAGR of 7.3% to attain a value of USD 6.2 billion by 2032. Other estimates state the global market size was USD 3.74 billion in 2024 and is projected to reach USD 6.09 billion by 2032, with a CAGR of 6.30%. The U.S. market alone was valued at USD 0.79 billion in 2024 and is expected to hit USD 1.13 billion by 2032. North America is likely to dominate the global diabetic nephropathy market, accounting for 35% of the share by 2025.

XORTX Therapeutics Inc. (NASDAQ: XRTX) is focused on several key programs and strategic initiatives that are expected to drive future revenue growth over the next 2-3 years. The company, currently in late-stage clinical development, anticipates generating revenue primarily from the commercialization of its pipeline assets and strategic collaborations.

Here are 3-5 expected drivers of future revenue growth:

1. Commercialization of XRx-026 (XORLO™) for Gout: XRx-026, XORTX's lead program, is in the final stages of development for treating gout in patients intolerant to allopurinol. The company is preparing for an NDA (New Drug Application) filing with the FDA, targeted within approximately 12 months, aiming for marketing approval by 2026. This program is positioned to address an estimated annual U.S. market opportunity of $700 million to over $1 billion.

2. Advancement and Potential Approval of XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD): XRx-008, developed with a proprietary oxypurinol formulation (XORLO™), is a late-stage clinical program for ADPKD. XORTX has received U.S. Orphan Drug Designation for XRx-008, which can accelerate the approval pathway. The company is conducting commercialization studies and is aiming for an "Accelerated Approval" NDA filing, potentially by 2025, with plans for a Phase 3 registration clinical trial. Analysts suggest the addressable market for XRx-008 could be 2-3 times larger than that currently served by Tolvaptan.

3. Integration and Development of the VB4-P5 Renal Anti-Fibrotic Program: XORTX is in the process of acquiring the VB4-P5 renal anti-fibrotic therapeutic program from Vectus Biosystems. This pre-IND stage program, focusing on novel chemical entities, aims to treat and prevent fibrosis in the kidney, targeting both rare and prevalent forms of progressive kidney disease. This acquisition expands XORTX's kidney disease portfolio and represents a new potential revenue stream through its future development and commercialization.

4. Strategic Partnerships for Commercialization: XORTX is actively pursuing strategic partnerships with major pharmaceutical and biotech companies with global reach. These collaborations are crucial for accelerating the commercialization of its lead programs, XRx-026 and XRx-008, by providing necessary funding, infrastructure, and market access, which could lead to upfront payments, milestone payments, and royalty revenues.

Share Repurchases

XORTX Therapeutics has not reported any share repurchases or authorized future share repurchases over the last 3-5 years.

Share Issuance

• In May 2025, XORTX Therapeutics announced a non-brokered private placement to raise up to USD $3,000,000 through the issuance of up to 3,409,090 common share units at a price of USD $0.88 per unit, with proceeds intended to advance gout programs and for working capital.
• In July 2025, the company announced a non-brokered private placement aiming to raise up to USD $114,500 by issuing up to 156,849 common share units at USD $0.73 per unit, with the offering closing in August 2025.
• In October 2025, XORTX Therapeutics completed a registered direct offering, generating gross proceeds of US$1,102,500.00 through the issuance of 572,470 common shares and 1,117,530 pre-funded warrants at US$0.63 per common share or pre-funded warrant.
• As of March 2026, the company is seeking shareholder approval for a share consolidation (reverse split) of up to five pre-consolidation shares for one post-consolidation share to meet Nasdaq's minimum bid price requirement.

Outbound Investments

• In October 2025, XORTX Therapeutics entered into a binding term sheet to acquire the VB4-P5 renal anti-fibrotic program from Vectus Biosystems for $3,000,000 in shares, with $293,803 in deferred acquisition costs recorded. The deadline for this acquisition was extended to March 31, 2026.

Capital Expenditures

• Capital expenditures for XORTX Therapeutics were reported as $5,370 for the third quarter of 2023, $7,205 for the second quarter of 2023, and $16,024 for the first quarter of 2023.
• For the full year 2022, capital expenditures totaled $15,988.
• A small portion of the company's resources is allocated to intellectual property development, and proceeds from financings are primarily used to advance drug programs and for general corporate purposes, which implicitly includes R&D-related capital outlays.